Evidence map›Paper›PMID 37074651›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Assessing Cytoskeletal Destruction During Pyroptosis.

Michael A Davis, Michael Gale

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Synthetic RIG-I-Agonist RNA Induces Death of Hepatocellular Carcinoma Cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael A DavisCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, USA. madphd@uw.edu.
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, USA.

Funding

Using the Collaborative Cross to discover immunoregulatory mechanisms that control WNV infectionR21AI145359 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2019 to 2020
$485k
NIAID NIH HHS R21 AI145359
6 · The paper itself

Abstract

Pyroptosis is an inflammatory form of cell death driven by the activation of caspase-1 and/or caspase-11 which cleaves and activates the pore-forming and cell-permeabilizing protein gasdermin-D. Pyroptosis is characterized by cell swelling and release of inflammatory cytosolic content, which were thought to be driven by colloid-osmotic lysis. Instead, we previously demonstrated that in vitro, pyroptotic cells do not in fact lyse. We also demonstrated that calpain cleaves vimentin, leading to loss of intermediate filaments, which in turn makes cells fragile and susceptible to rupture by extrinsic pressure. However, if, as our observations suggest, cells do not swell due to osmotic forces, what then causes cell rupture? Interestingly, in addition to intermediate filament loss, we demonstrated that other cytoskeletal networks, such as microtubules, actin, and nuclear lamina, are similarly lost during pyroptosis; however, the mechanisms driving these cytoskeletal disruptions as well as their functional significance are unclear. To facilitate the study of these processes, we present here the immunocytochemical methods by which we detected and assayed cytoskeletal destruction during pyroptosis.

Indexed as

CytoskeletonPyroptosisCaspasesCell DeathInflammasomesIntermediate FilamentsCaspasesInflammasomesActinCytoskeletonIntermediate filamentsLaminMicrotubulesNuclear laminaPyroptosisTubulinVimentin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.